Safety Concerns Halt Enrollment in Trial of Lilly, Centocor Stroke Treatment

Drug Industry Daily
KEYWORDS Markets / Trial

Eli Lilly and Centocor have temporarily suspended enrollment in a late-stage clinical trial of their heart treatment ReoPro after a review of preliminary trial data revealed a potential safety problem with the drug.

To View This Article:


Subscribe To Drug Industry Daily